BiotechTube
coremap

coremap

Cambridge, United States· Est.
coremapmedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

CoreMap is a private, pre-revenue medical device startup targeting the significant unmet need in treating persistent atrial fibrillation. Its core innovation is a proprietary micro-electrode mapping technology designed to overcome the critical limitations of current AF mapping systems—poor spatial resolution and inadequate sample density—by allowing physicians to 'see' the detailed electrical activity driving AF. With a seasoned leadership team, backing from venture capital firms, and a clear focus on a large cardiovascular market, CoreMap is developing a diagnostic tool intended to guide more effective, individualized curative ablation therapies.

Cardiovascular

Technology Platform

Proprietary micro-electrode design for ultra-high-resolution, high-density cardiac mapping to visualize complex atrial arrhythmias like atrial fibrillation.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The large and growing population of patients with persistent AF represents a major unmet need, as current ablation therapies have limited success.
Advances in personalized medicine and data-driven healthcare support the shift towards patient-specific diagnostic tools like CoreMap's.
The company could be an attractive strategic acquisition for a large EP player looking to enhance its mapping capabilities.

Risk Factors

The company faces significant technical risk in translating its novel electrode concept into a reliable, manufacturable commercial product.
Navigating the stringent FDA regulatory pathway for a new cardiac mapping device requires substantial time and capital.
The market is dominated by well-capitalized incumbents with established customer relationships, creating a high barrier to commercial entry.

Competitive Landscape

CoreMap competes in the cardiac electrophysiology mapping market, which is dominated by large medical device companies like Johnson & Johnson (Biosense Webster with the CARTO system) and Abbott (with the EnSite system). Other competitors include Boston Scientific and Medtronic. CoreMap's differentiation is its focused claim of superior resolution and sample density specifically for mapping complex AF, a segment where current technologies are acknowledged to be insufficient.

More companies in Digital Health & Biotech SaaS →More companies in United States →